US 9,518,126 B2 · Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

Abstract

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

Claims7

Dependent claims

An immunotherapeutic vaccine comprising immature myeloid cells (IMCs) loaded with a natural killer T cell ligand and a target antigen, the IMCs comprising natural killer T cell ligand loaded on CD1d and a target antigen loaded on major histocompatibility complex (MHC) molecules,

wherein the IMCs are obtained from a tumor-bearing subject;
wherein the IMCs express GR-1 and CD11b simultaneously on their surface;
wherein the natural killer T cell ligand is α-galactosylceramide;
wherein the target antigen is a fragment of a full-length protein derived from a tumor or a pathogen;
and
wherein the vaccine activates cytotoxic T cells specific for said target antigen.

3 more elements

Dependencies are inferred from the claim text.

Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

Life of this patent

Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

Life of this patent

Abstract

Claims7